TET2 ADDITIONAL MUTATIONS AT DIAGNOSIS IMPACT THE RESPONSE OF FIRST-LINE TREATMENT WITH HYDROXYUREA OR INTERFERON-Α IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Carole Mosnier, 419096

UNVEILING THE EFFECTIVENESS AND PREDICTIVE FACTORS OF JAKTINIB TREATMENT IN MYELOFIBROSIS PATIENTS WITH ANEMIA

EHA Library, Huafeng Wang, 419118

THROMBOSIS RATES FOR MPN PATIENTS BY ATTAINED AGE AND TIME SINCE DIAGNOSIS: A SWEDISH REGISTER-BASED MATCHED-COHORT STUDY

EHA Library, Nurgul Batyrbekova, 419119

DECIPHERING THE PREDICTORS OF DEATH IN POLYCYTHEMIA VERA: FOCUS ON THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AND THE INCIDENCE OF ARTERIAL THROMBOSIS

EHA Library, Tiziano Barbui, 419122

EFFICACY OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS WHO HAVE OVERLAPPING THROMBOCYTOPENIA AND ANEMIA

EHA Library, Pankit Vachhani, 419124

REAL-WORLD DATA ON DIRECT ORAL ANTICOAGULANTS IN BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A MULTICENTER STUDY ON BEHALF OF SUBCOMMITTEE ON MPNS FOR TURKISH SOCIETY OF HEMATOLOGY

EHA Library, Mehmet Baysal, 419125

CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 419127

REVISED “IRR6” MODEL IN INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 419128

RUXOLITINIB STARTING DOSE REDUCTION AFFECT OVERALL SURVIVAL IN MYELOFIBROSIS: AIFA MONITORING REGISTRIES ANALYSIS

EHA Library, Massimo Breccia, 419130

THE IMPACT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN 2233 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: RESULTS FROM THE EXPANDED-ACCESS JUMP STUDY

EHA Library, Haifa Kathrin Al-Ali, 419131

IMPACT OF CALR MUTATION TYPE AND NON-DRIVER MUTATIONS ON THE RESPONSE TO CYTOREDUCTIVE TREATMENT AND OUTCOMES IN PATIENTS INCLUDED IN THE SPANISH REGISTRY OF ESSENTIAL THROMBOCYTHEMIA (RETE)

EHA Library, Marta Santaliestra Tomas, 419133

HIGH RATE OF DISEASE PROGRESSION IN PATIENTS WITH LOW-RISK MYELOFIBROSIS (MF) ENROLLED IN THE PROSPECTIVE MOST STUDY

EHA Library, Michael Grunwald, 419140

COMPREHENSIVE EVALUATION OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS: FINAL ANALYSIS RESULTS FROM A RANDOMIZED PHASE 3 STUDY

EHA Library, Huafeng Wang, 419141

HIGH RESOLUTION CHEST COMPUTED TOMOGRAPHY RESPONSES FOR A COHORT OF ADULT WITH PULMONARY LANGERHANS CELL HISTIOCYTOSIS

EHA Library, Long Chang, 419143

A PHASE 1B TRIAL OF DISC-0974, AN ANTI-HEMOJUVELIN ANTIBODY, IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA

EHA Library, Naseema Gangat, 419146

EVALUATING MYELODYSPLASIA RELATED MUTATIONS BY ELN 2022 CLASSIFICATION AND IT IMPACT ON ACCELERATED PHASE AND BLAST PHASE MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Verna Cheung, 419150

CLINICAL AND MOLECULAR CHARACTERISATION OF PATIENTS WITH LOW JAK2V617F ALLELE BURDEN: INSIGHTS FROM LONGITUDINAL FOLLOW-UP

EHA Library, Nieves Garcia-Gisbert, 419151

BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 IN PATIENTS WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY

EHA Library, Pankit Vachhani, 419152

IMPACT OF GENETIC FACTORS IN THE OVERALL SURVIVAL OF PATIENTS WITH CALR-MUTATED MYELOFIBROSIS

EHA Library, Ruth Stuckey, 419153

REAL-WORLD OUTCOMES OF MOMELOTINIB AS AN ALTERNATIVE THERAPY TO OTHER JAK INHIBITORS IN MYELOFIBROSIS PATIENTS WITH ANEMIA.

EHA Library, Valentin Garcia-Gutierrez, 419154

CPH DEEP NEURAL NETWORK AND CONTINUOUS-TIME MULTI-STATE MARKOV CHAIN MODELS CONFIRM HMA TO BE THE BEST FIRST LINE TREATMENT OPTION FOR CMML PATIENTS – AN INTERNATIONAL STUDY COORDINATED BY THE AGMT

EHA Library, Lisa Pleyer, 419155

SELINEXOR PLUS RUXOLITINIB IMPACT ON SYMPTOM BURDEN IN PATIENTS WITH MYELOFIBROSIS AND POTENTIAL MECHANISM OF ACTION VIA INHIBITION OF NF-ΚB AND ACTIVATION OF P53 PATHWAYS

EHA Library, Srinivas Tantravahi, 419156

CLINICAL PATTERNS AND THERAPEUTIC CONSIDERATIONS IN MALIGNANT HISTIOCYTOSES: A NATIONWIDE RETROSPECTIVE ANALYSIS

EHA Library, Camille Bigenwald, 419158

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MYELOFIBROSIS TREATED WITH PACRITINIB IN THE UNITED STATES

EHA Library, John Mascarenhas, 419159

IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH SECONDARY MYELOFIBROSIS

EHA Library, Nico Gagelmann, 419161

DECIPHERING THROMBOTIC COMPLICATIONS AND INFLAMMATORY FACTORS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND ATRIAL FIBRILLATION: A MULTI-CENTRE RETROSPECTIVE STUDY

EHA Library, Olga Chyrko, 419163

BRENTUXIMAB VEDOTIN (BV)+AVD IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTRIC STUDY

EHA Library, Giovanni Manfredi Assanto, 419167

LONG-TERM CAUSE-SPECIFIC MORTALITY IN A COHORT OF 1,435 HODGKIN LYMPHOMAS TREATED AT THE NATIONAL ADULT PUBLIC CANCER PROGRAM IN CHILE OVER A 30-YEAR PERIOD

EHA Library, Massimo Federico, 419171

EVALUATION OF GONADAL FUNCTION IN YOUNG MEN AND WOMEN DIAGNOSED WITH HODGKIN LYMPHOMA

EHA Library, Angeliki Georgopoulou, 419172

PEMBROLIZUMAB PLUS THE ANTI–LAG-3 ANTIBODY FAVEZELIMAB FOR ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA: AN UPDATED ANALYSIS OF A PHASE 1/2 STUDY

EHA Library, Peter Borchmann, 419174

KEYNOTE-667: RESULTS FROM THE PHASE 2 STUDY OF PEMBROLIZUMAB (PEMBRO) IN CHILDREN AND YOUNG ADULTS WITH LOW-RISK CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY

EHA Library, Lisa Giulino-Roth, 419175

BRENTUXIMAB VEDOTIN - ESHAP SIGNIFICANTLY INCREASES THE METABOLIC COMPLETE REMISSION RATE VERSUS ESHAP IN RELAPSED CLASSICAL HODGKIN’S LYMPHOMA. FINAL RESULTS OF THE BRESELIBET PROSPECTIVE TRIAL.

EHA Library, Anna Sureda Balari, 419180

ANIMATE: A UK PHASE II PET RESPONSE-ADAPTED TRIAL OF NIVOLUMAB IN RELAPSED / REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Graham Collins, 419182

THE ADDITIONAL PROGNOSTIC VALUE OF ΔSUVMAX TO THE FIRST-LINE TREATMENT OF CLASSICAL HODGKIN LYMPHOMA

EHA Library, Laszlo Pinczes, 419185

FAVORABLE, CONTEMPORARY, REAL-WORLD OUTCOMES OF BRENTUXIMAB VEDOTIN AS POST-ASCT CONSOLIDATION IN RRHL: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Anna Sureda Balari, 419188

COMBINATION OF BRENTUXIMAB VEDOTIN AND PEMBROLIZUMAB BEFORE INTENSIFICATION WITH AUTOLOGOUS STEM CELL TRANSPLANTATION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA.

EHA Library, Hanne Massa, 419192

OUTCOME OF PATIENTS WITH LIMITED-STAGE HODGKIN LYMPHOMA (HL) ENROLLED IN THE EORTC/LYSA/FIL H10 AND PROGRESSED/RELAPSED AFTER INITIAL THERAPY

EHA Library, Manuel Gotti, 419194

TUMOR ASSOCIATED MACROPHAGES’ CYTOKINES; CD163, CCL4 AND CCL2, AS POSSIBLE NEW BIOMARKERS IN WALDENSTROM’S MACROGLOBULINEMIA.

EHA Library, Alexandros Gkiokas, 419196

SAFETY AND EFFICACY RESULTS OF A PHASE 1 STUDY OF THE NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) FOR RELAPSED/REFRACTORY WALDENSTRÖM'S MACROGLOBULINEMIA

EHA Library, Chan Y. Cheah, 419197

RELAPSE PATTERNS AND OUTCOMES OF PATIENTS WITH FOLLICULAR LYMPHOMA ACHIEVING COMPLETE METABOLIC RESPONSE AFTER INDUCTION THERAPY. A FIL FOLL12 SUB-STUDY.

EHA Library, Maria Elena Nizzoli, 419198

COMBINATION TREATMENT WITH NOVEL BCL-2 INHIBITOR SONROTOCLAX (BGB-11417) AND ZANUBRUTINIB INDUCES HIGH RATE OF COMPLETE REMISSION FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) MCL

EHA Library, Constantine S. Tam, 419199

WAVE STUDY, A RETROSPECTIVE OF FILO TRIAL : PATIENTS WITH RELAPSE WALDENSTRÖM'S MACROGLOBULINEMIA TREATED BY VENETOCLAX IN REAL LIFE

EHA Library, Mathilde Vonfeld, 419200

PRELIMINARY EFFICACY AND SAFETY OF THE BRUTON TYROSINE KINASE (BTK) DEGRADER BGB-16673 IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) INDOLENT NHL: RESULTS FROM THE PHASE 1 BGB-16673-101 STUDY

EHA Library, Chan Y. Cheah, 419206

SUBGROUP ANALYSES IN PATIENTS WITH R/R MCL TREATED WITH LISOCABTAGENE MARALEUCEL BY PRIOR LINES OF THERAPY AND RESPONSE TO BRUTON TYROSINE KINASE INHIBITOR FROM THE TRANSCEND NHL 001 MCL COHORT

EHA Library, Manali Kamdar, 419213

RESPONSE-ADAPTED TREATMENT WITH MOSUNETUZUMAB WITH OR WITHOUT OBINUTUZUMAB AND POLATUZUMAB VEDOTIN IN TREATMENT NAÏVE FOLLICULAR AND MARGINAL ZONE LYMPHOMA: INTERIM RESULTS AND PHASED-SEQ MRD ANALYSIS

EHA Library, Ryan Lynch, 419214

EFFICACY AND SAFETY OF IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) AND TP53 MUTATIONS IN THE SYMPATICO STUDY

EHA Library, Wojciech Jurczak, 419215

VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL OR ARI-0001) IN RELAPSED / REFRACTORY ADULT FOLLICULAR LYMPHOMA

EHA Library, Nuria Martinez-Cibrian, 419217

IMPACT OF TP53 MUTATION ALLELIC BURDEN ON OUTCOME OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: A STUDY FROM COMMAND CONSORTIUM.

EHA Library, Talha Badar, 419120

PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND HEALTH OUTCOMES IN A REAL-WORLD POPULATION OF PATIENTS WITH MYELOFIBROSIS TREATED WITH FEDRATINIB

EHA Library, Francesco Passamonti, 419121

AGE-DEPENDENT LINK BETWEEN ARTERIAL THROMBOSIS AND SECONDARY CANCER IN PH-NEG MPN: CASE-CONTROL STUDY INSIGHTS

EHA Library, Tiziano Barbui, 419123

LONG TERM FOLLOW-UP RESULTS OF PHASE II CLINICAL TRIAL EVALUATING RUXOLITINIB (RUX) AND AZACITIDINE (AZA) COMBINATION THERAPY IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

EHA Library, Sankalp Arora, 419126

A PHASE 2 STUDY OF PEMIGATINIB (FIGHT-203; INCB054828) IN PATIENTS WITH MYELOID/LYMPHOID NEOPLASMS WITH FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE REARRANGEMENT

EHA Library, Alessandro Vannucchi, 419129

ANALYSIS OF CARDIOVASCULAR RISK IN 920 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS USING NATURAL LANGUAGE PROCESSING

EHA Library, Andrea Duminuco, 419132

A REAL-WORLD EVALUATION OF RISK FACTORS FOR DISEASE PROGRESSION IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL

EHA Library, Michael Grunwald, 419134

THE TRIPLE A MODEL-AAA (AGE, ABSOLUTE NEUTROPHIL COUNT, ABSOLUTE LYMPHOCYTE COUNT) PREDICTS SURVIVAL AND THROMBOSIS IN POLYCYTHEMIA VERA

EHA Library, Ivan Krecak, 419135

RUXOLITINIB TREATMENT IN PATIENTS WITH POLYCYTHEMIA VERA REDUCES JAK2 ALLELE BURDEN AND IMPROVES HEMATOCRIT CONTROL AND SYMPTOM BURDEN

EHA Library, Claire Harrison, 419136

NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN POLYCYTHEMIA VERA (PV): CORRELATION WITH ROPEG-INTERFERON RESPONSE IN LOW PV TRIAL

EHA Library, Tiziano Barbui, 419137

FEDRATINIB IN PATIENTS WITH MYELOFIBROSIS EXPOSED TO RUXOLITINIB: AN INDIRECT TREATMENT COMPARISON WITH MOMELOTINIB AND PACRITINIB

EHA Library, Francesca Palandri, 419138

INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION

EHA Library, Francesca Palandri, 419139

SYMPTOM-FOCUSED RESULTS FROM SUMMIT PART 1: AN ONGOING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL OF BEZUCLASTINIB IN ADULT PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Lindsay Rein, 419142

A NEW MACHINE LEARINING CLINICAL SCORE FOR THROMBOSIS RISK IN POLYCYTHEMIA VERA: THROMBOVERA CS

EHA Library, Isidora Arsenovic, 419144

‘REAL WORLD ANALYSIS APPLYING INTERNATIONAL PROGNOSTIC SCORE (IPSM) IN NON-ADVANCED SYSTEMIC MASTOCYTOSIS PATIENTS IN UK SINGLE CENTRE OF EXCELLENCE’

EHA Library, Priya Sriskandarajah, 419145

THE ACTIVIN RECEPTOR-LIKE KINASE-2 INHIBITOR ZILURGISERTIB (INCB000928) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS: PHASE 1/2 STUDY RESULTS

EHA Library, Prithviraj Bose, 419147

RECOGNITION OF SYMPTOM BURDEN IN MPN: DISCREPANCIES BETWEEN  PATIENT- AND PHYSICIAN-REPORTED ASSESSMENT – AN INTRA-INDIVIDUAL ANALYSIS BY THE GERMAN MPN STUDY GROUP (GSG-MPN)

EHA Library, Susanne Isfort, 419148

PROGNOSTIC IMPACT OF LEUKOCYTOSIS, MONOCYTOSIS AND EOSINOPHILIA IN ADVANCED SYSTEMIC MASTOCYTOSIS: A REGISTRY-BASED ANALYSIS OF THE GREM

EHA Library, Johannes Lübke, 419149

LENALIDOMIDE AND DEXAMETHASONE FOR ROSAI-DORFMAN DISEASE: A SINGLE ARM, SINGLE CENTER, PROSPECTIVE PHASE 2 STUDY

EHA Library, Long Chang, 419157

PREVALENCE OF POLYCYTHEMIA VERA, CYTOREDUCTIVE TREATMENT, AND THROMBOEMBOLIC EVENTS IN AFFECTED PATIENTS: A STUDY BASED ON LONGITUDINAL GERMAN HEALTH CLAIMS DATA

EHA Library, Haifa Al-Ali, 419160

GERMLINE INACTIVATING VARIANTS IN SH2B3 DEFINE A NOVEL DISORDER CHARACTERIZED BY A TRANSIENT NEONATAL/INFANCY MYELOPROLIFERATIVE DISORDER AND SUBSEQUENT DEVELOPMENT OF THROMBOCYTOSIS IN CHILDHOOD

EHA Library, Davide Leardini, 419162

ENHANCING ACCURACY AND SAFETY OF AI-BASED BONE MARROW ASSESSMENT IN MPNS WITH AN AUTOMATED QUALITY CONTROL PIPELINE

EHA Library, Xuezi Hu, 419164

ADVANCED-STAGE HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (A-HIPI) IN TURKISH CLASSICAL HODGKIN LYMPHOMA PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Oguzhan Koca, 419165

TREATMENT OF ADVANCED STAGE, HIGH RISK SCORE HODGKIN'S DISEASE PATIENTS WITH CONVENTIONAL CHEMOTHERAPY PLUS BRENTUXIMAB VEDOTIN AND NIVOLUMAB: A PHASE II TRIAL RESULTS

EHA Library, Maher Salamoon, 419166

GERIATRIC FITNESS AND REAL-LIFE OUTCOMES IN ELDERLY PATIENTS WITH HODGKIN’S LYMPHOMA

EHA Library, Silvio Ligia, 419168

CONGESTIVE HEART FAILURE FOLLOWING ANTHRACYCLINE-CONTAINING TREATMENT FOR CLASSICAL HODGKIN LYMPHOMA: A SWEDISH MATCHED COHORT STUDY

EHA Library, Sissel Johanne Godtfredsen, 419169

PEMBROLIZUMAB PLUS THE ANTI–LAG-3 ANTIBODY FAVEZELIMAB FOR HEAVILY PRETREATED ANTI–PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): AN UPDATED ANALYSIS OF A PHASE 1/2 STUDY

EHA Library, Gareth Gregory, 419170

BENDAMUSTINE AND ADCETRIS IN UNTREATED HODGKIN LYMPHOMA OF THE ELDERLY: LONG-TERM RESULTS OF THE HALO TRIAL

EHA Library, Andrea Gallamini, 419173

RADIOTHERAPY-FREE TREATMENT IN GOOD PROGNOSIS EARLY-STAGE HODGKIN LYMPHOMA (RAFTING TRIAL-NCT ID.04866654). RESULTS OF PATIENT STRATIFICATION.

EHA Library, Jan Maciej Zaucha, 419176

INNOVATIVE EVA REGIMEN (ETOPOSIDE, VINBLASTINE, DOXORUBICIN) IN HODGKIN'S LYMPHOMA TREATMENT FOR PREGNANT WOMEN.

EHA Library, Joanna Romejko-Jarosińska, 419177

DATA REQUIREMENTS FOR DEVELOPMENT OF PREDICTION MODELS FOR SURVIVAL AMONG HODGKIN LYMPHOMA PATIENTS: HOW MANY PATIENTS ARE NEEDED?

EHA Library, Rasmus Rask Kragh Jørgensen, 419178

BASELINE PET-CT RADIOMICS PREDICT 5-YEAR PROGRESSION FREE SURVIVAL IN ADVANCED STAGE HODGKIN LYMPHOMA

EHA Library, Fer de Wit, 419179

EARLY DETECTION OF CLASSIC HODGKIN LYMPHOMA RELAPSE USING ROUTINE SERUM TARC MEASUREMENTS DURING FOLLOW-UP

EHA Library, Sophie Teesink, 419181

BRENTUXIMAB-VEDOTIN PLUS AVD CHEMOTHERAPY AS FRONTLINE THERAPY IN PATIENTS WITH STAGE IV CLASSICAL HODGKIN LYMPHOMA: A REAL-WORLD REPORT ON FEASIBILITY, EFFICACY AND INTERIM-PET RESULTS

EHA Library, Chiara Rusconi, 419183

KEYNOTE-667: UPDATED RESULTS FROM THE PHASE 2 STUDY OF PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH HIGH-RISK CLASSICAL HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE (SER) TO FRONT-LINE CHEMOTHERAPY

EHA Library, Christine Mauz-Koerholz, 419184

TREATMENT EFFECTS OF BRECADD ON HEALTH-RELATED QUALITY OF LIFE: AN ANALYSIS OF PATIENT REPORTED OUTCOMES IN THE RANDOMIZED INTERNATIONAL PHASE III GERMAN HODGKIN STUDY GROUP HD21 TRIAL

EHA Library, Justin Ferdinandus, 419187

SAFETY AND EFFICACY OF SYK INHIBITOR SOVLEPLENIB IN HEAVILY PRE-TREATED HODGKIN LYMPHOMA PATIENTS

EHA Library, Paolo Strati, 419189

SAFETY AND EFFICACY RESULTS FROM AN OPEN-LABEL PHASE 1/2 TRIAL OF SABESTOMIG (AZD7789) IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA PREVIOUSLY TREATED WITH ANTI-PD-(L)1 THERAPIES

EHA Library, Gaetano Corazzelli, 419190

A NATIONWIDE STUDY OF NEWLY DIAGNOSED NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA OVER TWO DECADES

EHA Library, Katrin Bamdeg-Hvolbek, 419191

BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: SEVEN-YEAR OVERALL SURVIVAL ANALYSIS FROM THE ECHELON-1 STUDY

EHA Library, John Radford, 419193

TIMING MATTERS: IMPACT OF EARLY HISTOLOGICAL TRANSFORMATION ON SURVIVAL IN FOLLICULAR LYMPHOMA (FL) PATIENTS: A MULTICENTRE ANALYSIS

EHA Library, Andrea Franch, 419195

PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA TREATED WITH EPCORITAMAB

EHA Library, Wojciech Jurczak, 419201

SPLENOMEGALY AT THE TIME OF LGLL DIAGNOSIS IS ASSOCIATED WITH POOR DISEASE OUTCOMES AND EXPANSION OF LGLL CLONES.

EHA Library, Ahmad Kiwan, 419202

CLINICAL FEATURES AND GENETIC ALTERATIONS ASSOCIATED WITH HISTOLOGIC GRADING OF FOLLICULAR LYMPHOMA

EHA Library, Huilai Zhang, 419203

BENEFIT OF RITUXIMAB MAINTENANCE AFTER FIRST-LINE BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Yucai Wang, 419204

IBRUTINIB, LENALIDOMIDE AND RITUXIMAB IN RELAPSED MANTLE CELL LYMPHOMA - LONG TERM FOLLOW-UP OF THE NORDIC LYMPHOMA GROUP MCL6 PHILEMON TRIAL

EHA Library, Elin Forsgren, 419205

ZR STUDY：A PROSPECTIVE PHASE II STUDY OF ZANUBRUTINIB-RITUXIMAB INDUCTION WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN UNTREATED MANTLE CELL LYMPHOMA

EHA Library, Chang-Ju Qu, 419207

MATCHING-ADJUSTED INDIRECT COMPARISONS OF EPCORITAMAB VS MOSUNETUZUMAB OR ODRONEXTAMAB IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AFTER ≥2 SYSTEMIC THERAPIES

EHA Library, Alexey Danilov, 419208

RESULTS FROM THE FOLLICULAR LYMPHOMA (FL) OUTCOMES IN RELAPSED/REFRACTORY (R/R) PATIENTS TREATED WITH SYSTEMIC THERAPY IN A REAL-WORLD ASSESSMENT (FLORA) STUDY

EHA Library, Emmanuel Bachy, 419209

MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB VERSUS REAL-WORLD CHEMOIMMUNOTHERAPY (CIT) OR CHEMOTHERAPY (CHEMO) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

EHA Library, Renata Walewska, 419210

REAL-WORLD EVALUATION OF TREATMENT PATTERN, TIME TO NEXT TREATMENT, HEALTHCARE RESOURCE UTILIZATION, AND COST OF CARE IN FOLLICULAR LYMPHOMA

EHA Library, Sameh Gaballa, 419211

TP53 AND CDKN2A DISRUPTIONS ARE INDEPENDENT PROGNOSTIC DRIVERS IN MANTLE CELL LYMPHOMA: LONG TERM OUTCOME OF THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 TRIAL

EHA Library, Riccardo Moia, 419212

CLINICAL CHARACTERISTICS AND OUTCOMES OF MCL PATIENTS AGED 80 YEARS AND OLDER

EHA Library, Simon Pahnke, 419216